Chris Moreau
Amministratore Delegato presso ALGERNON PHARMACEUTICALS INC.
Patrimonio netto: 127 420 $ in data 31/05/2024
Profilo
Christopher Joseph Moreau is currently the Chief Executive Officer & Director at Algernon Pharmaceuticals, Inc. He previously held positions as the President, CEO, Director & Head-Investor Relations at Luminor Medical Technologies, Inc. from 2011 to 2015.
He also served as the Chief Executive Officer at Nash Pharmaceuticals, Inc. Additionally, he was a Director at First Responder Technologies, Inc. from 2019 to 2020.
He has also held the position of President at Advansis Capital Corp.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 27/06/2024 | 1 108 002 ( 5.54% ) | 127 420 $ | 31/05/2024 |
Posizioni attive di Chris Moreau
| Società | Posizione | Inizio |
|---|---|---|
| ALGERNON PHARMACEUTICALS INC. | Amministratore Delegato | 01/03/2018 |
Precedenti posizioni note di Chris Moreau
| Società | Posizione | Fine |
|---|---|---|
| QUEBEC HOLDINGS PEGMATITE | Presidente | 24/07/2019 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Amministratore Delegato | 21/04/2016 |
Nash Pharmaceuticals, Inc.
 Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Amministratore Delegato | - |
| Advansis Capital Corp. | Presidente | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ALGERNON PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Commercial Services |
| Advansis Capital Corp. | |
First Responder Technologies, Inc.
 First Responder Technologies, Inc. Aerospace & DefenseElectronic Technology First Responder Technologies, Inc. is in the process of exploring business opportunities. The company was founded on January 27, 2017 and is headquartered in Vancouver, Canada. | Electronic Technology |
Nash Pharmaceuticals, Inc.
Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Health Technology |
- Borsa valori
- Insiders
- Chris Moreau
